海翔药业：股票交易异常波动

Core Viewpoint - The stock of Haixiang Pharmaceutical experienced an abnormal trading fluctuation, with a cumulative closing price increase of over 20% over three consecutive trading days from February 6 to February 10, 2026 [1] Group 1: Stock Performance - The company confirmed that there were no significant changes in its operational environment and that its business operations remain normal [1] - The controlling shareholder and actual controller did not engage in any buying or selling of the company's shares during the period of stock fluctuation [1] Group 2: Share Buyback - The company approved a share repurchase plan on April 9, 2025, and as of February 10, 2026, it has repurchased a total of 14,315,300 shares, accounting for 0.8844% of the total share capital, with a total transaction amount of 88,881,298.38 yuan [1] Group 3: Investment and Market Activity - The partnership in which the company invested completed the conversion of its unlisted shares of Fuhong Hanlin on February 4, 2026, and these shares have been listed on the Hong Kong Stock Exchange [1] - The company confirmed that there are no undisclosed significant matters that could impact its stock price [1]